GTER - Grupo Terapêutico Espiritual Reflexivo

Managing PD-1 resistant head and neck cancer presents unique clinical challenges. Patients may experience initial improvement followed by disease progression, creating uncertainty for both clinicians and patients.

Determining when resistance has developed requires careful monitoring and imaging interpretation. Symptoms may not always reflect underlying changes, making early detection difficult.

Treatment decisions must balance efficacy, toxicity, and quality of life. Switching therapies too early or too late can affect outcomes. Multidisciplinary collaboration is essential in navigating these complex choices.

Despite challenges, resistance has driven innovation. Each limitation has sparked new research into alternative immune pathways and combination therapies.